92
Views
2
CrossRef citations to date
0
Altmetric
Rheumatoid Arthritis

64Cu-ATSM and 99mTc(CO)3-DCM20 potential in the early detection of rheumatoid arthritis

, ORCID Icon, , , , & show all
Pages 350-356 | Received 21 Jan 2020, Accepted 01 Apr 2020, Published online: 23 Apr 2020

References

  • Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018;320(13):1360–72.
  • Colebatch AN, Edwards CJ, Østergaard M, van der Heijde D, Balint PV, D’Agostino MA, et al. EULAR recommendations for the use of imaging of the joints in the clinical management of rheumatoid arthritis. Ann Rheum Dis. 2013;72(6):804–14.
  • Mountz JM, Alavi A, Mountz JD. Emerging optical and nuclear medicine imaging methods in rheumatoid arthritis. Nat Rev Rheumatol. 2012;8(12):719–28.
  • Put S, Westhovens R, Lahoutte T, Matthys P. Molecular imaging of rheumatoid arthritis: emerging markers, tools, and techniques. Arthritis Res Ther. 2014;16(2):208.
  • Kubota K, Ito K, Morooka M, Mitsumoto T, Kurihara K, Yamashita H, et al. Whole-body FDG-PET/CT on rheumatoid arthritis of large joints. Ann Nucl Med. 2009;23(9):783–91.
  • Okamura K, Yonemoto Y, Arisaka Y, Takeuchi K, Kobayashi T, Oriuchi N, et al. The assessment of biologic treatment in patients with rheumatoid arthritis using FDG-PET/CT. Rheumatology (Oxford). 2012;51(8):1484–91.
  • Suto T, Okamura K, Yonemoto Y, Okura C, Tsushima Y, Takagishi K. Prediction of large joint destruction in patients with rheumatoid arthritis using 18F-FDG PET/CT and disease activity score. Medicine (Baltimore) 2016;95:e2841.
  • Matsui T, Nakata N, Nagai S, Nakatani A, Takahashi M, Momose T, et al. Inflammatory cytokines and hypoxia contribute to 18F-FDG uptake by cells involved in pannus formation in rheumatoid arthritis. J Nucl Med. 2009;50(6):920–6.
  • Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4(1):18001.
  • Siouti E, Andreakos E. The many facets of macrophages in rheumatoid arthritis. Biochem Pharmacol. 2019;165:152–69.
  • Chung SJ, Yoon HJ, Youn H, Kim MJ, Lee YS, Jeong JM, et al. 18F-FEDAC as a targeting agent for activated macrophages in DBA/1 mice with collagen-induced arthritis: comparison with 18F-FDG. J Nucl Med. 2018;59(5):839–45.
  • Gent YY, Ter Wee MM, Voskuyl AE, den Uyl D, Ahmadi N, Dowling C, et al. Subclinical synovitis detected by macrophage PET, but not MRI, is related to short-term flare of clinical disease activity in early RA patients: an exploratory study. Arthritis Res Ther. 2015;17(1):266.
  • Narayan N, Owen DR, Mandhair H, Smyth E, Carlucci F, Saleem A, et al. Translocator protein as an imaging marker of macrophage and stromal activation in rheumatoid arthritis pannus. J Nucl Med. 2018;59(7):1125–32.
  • Put S, Schoonooghe S, Devoogdt N, Schurgers E, Avau A, Mitera T, et al. SPECT imaging of joint inflammation with Nanobodies targeting the macrophage mannose receptor in a mouse model for rheumatoid arthritis. J Nucl Med. 2013;54(5):807–14.
  • Abbruzzese B, Zubal G, Behr S, Ralph D, Shuping J, Colborn D, et al. Macrophage CD206 receptor targeting with 99mTc-tilmanocept permits specific quantitative diagnostic imaging of active rheumatoid arthritis (RA) and id differentiated from osteoarthritis (OA). J Nucl Med 2017;58:303.
  • Kardan A, Abbruzzese B, Kissling A, Haynam M, Ralph D, Hershey R, et al. Intravenous 99mTc-tilmanocept in planar and fused SPECT/CT imaging of activated macrophage infiltration in subjects with active rheumatoid arthritis. J Nucl Med 2018;59:110.
  • Kardan A, Kissling A, Hartings C, Hershey R, Blue M, Ralph D, et al. A phase I/phase II study of intravenously (IV) administered Tc 99m tilmanocept (TCT) to determine safety, tolerability, optimal clinical dose selection, and imaging timepoint in patients clinically diagnosed with rheumatoid arthritis (RA). J Nucl Med 2019;60:89.
  • Pirmettis I, Arano Y, Tsotakos T, Okada K, Yamaguchi A, Uehara T, et al. New 99mTc(CO)3 mannosylated dextran bearing S-derivatized cysteine chelator for sentinel lymph node detection. Mol Pharm. 2012;9(6):1681–92.
  • Yamaguchi A, Hanaoka H, Pirmettis I, Uehara T, Tsushima Y, Papadopoulos M, et al. Injection site radioactivity of 99mTc-labeled mannosylated dextran for sentinel lymph node mapping. Mol Pharm. 2015;12(2):514–9.
  • Fuchs K, Kuehn A, Mahling M, Guenthoer P, Hector A, Schwenck J, et al. In vivo hypoxia PET imaging quantifies the severity of arthritic joint inflammation in line with overexpression of hypoxia-inducible factor and enhanced reactive oxygen species generation. J Nucl Med. 2017;58(5):853–60.
  • Quinonez-Flores CM, Gonzalez-Chavez SA, Pacheco-Tena C. Hypoxia and its implications in rheumatoid arthritis. J Biomed Sci. 2016;23(1):62.
  • Fearon U, Canavan M, Biniecka M, Veale DJ. Hypoxia, mitochondrial dysfunction and synovial invasiveness in rheumatoid arthritis. Nat Rev Rheumatol. 2016;12(7):385–97.
  • Hua S, Dias TH. Hypoxia-inducible factor (HIF) as a target for novel therapies in rheumatoid arthritis. Front Pharmacol. 2016;7:184
  • Lopci E, Grassi I, Chiti A, Nanni C, Cicoria G, Toschi L, et al. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging 2014;4(4):365–84.
  • Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008;49(Suppl_2):129S–48S.
  • Fujibayashi Y, Cutler CS, Anderson CJ, McCarthy DW, Jones LA, Sharp T, et al. Comparative studies of Cu-64-ATSM and C-11-acetate in an acute myocardial infarction model: ex vivo imaging of hypoxia in rats. Nucl Med Biol. 1999;26(1):117–21.
  • Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protoc. 2007;2(5):1269–75.
  • Brand DD. Rodent models of rheumatoid arthritis. Comp Med. 2005;55(2):114–22.
  • McCarthy DW, Shefer RE, Klinkowstein RE, Bass LA, Margeneau WH, Cutler CS, et al. Efficient production of high specific activity 64Cu using a biomedical cyclotron. Nucl Med Biol. 1997;24(1):35–43.
  • Obata A, Kasamatsu S, McCarthy DW, Welch MJ, Saji H, Yonekura Y, et al. Production of therapeutic quantities of 64Cu using a 12 MeV cyclotron. Nucl Med Biol. 2003;30(5):535–9.
  • Giulia Anna F, De Feo MS, De Vincentis G, Monteleone F, Liberatore M. Radiopharmaceuticals labelled with copper radionuclides: clinical results in human beings. Curr Radiopharm. 2018;11(1):22–33.
  • Tsuchimochi M, Hayama K. Intraoperative gamma cameras for radioguided surgery: technical characteristics, performance parameters, and clinical applications. Phys Medica. 2013;29(2):126–38.
  • Woodell-May JE, Sommerfeld SD. Role of inflammation and the immune system in the progression of osteoarthritis. J Orthop Res. 2020;38(2):253–7.
  • Rizzo A, Ferrante A, Guggino G, Ciccia F. Gut inflammation in spondyloarthritis. Best Pract Res Clin Rheumatol. 2017;31(6):863–76.
  • Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun. 2018;93:24–36.
  • Biddlestone J, Bandarra D, Rocha S. The role of hypoxia in inflammatory disease (review). Int J Mol Med. 2015;35(4):859–69.
  • MacDonald IJ, Liu SC, Su CM, Wang YH, Tsai CH, Tang CH. Implications of angiogenesis involvement in arthritis. IJMS. 2018;19(7):2012.
  • McCall KC, Humm JL, Bartlett R, Reese M, Carlin S. Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia. Int J Radiat Oncol. 2012;84(3):e393–e9.
  • Jeon CH, Ahn JK, Chai JY, Kim HJ, Bae EK, Park SH, et al. Hypoxia appears at pre-arthritic stage and shows co-localization with early synovial inflammation in collagen induced arthritis. Clin. Exp. Rheumatol 2008;26(4):646–8.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.